Effect of Xen Implantation on the Aqueous Humor Proteome

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04141865

Enrollment

Registered

2019-10-28

Start date

2019-10-24

Completion date

2022-02-15

Last updated

2022-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Open Angle Glaucoma

Brief summary

The purpose of this study is to determine how the aqueous humor proteome changes after implantation of a Xen microstent for treatment of glaucoma.

Detailed description

The purpose of this study is to determine how the aqueous humor proteome changes after implantation of a Xen microstent for treatment of glaucoma using liquid chromatography mass spectrometry.

Interventions

DEVICEXen

Xen microstent implantation

DEVICEAqueous shunt

Aqueous shunt implantation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Male or female of any racial or ethnic origin, 18 years or older * Able to provide written informed consent. * Scheduled to undergo Xen implantation for open angle glaucoma or already has an aqueous shunt

Exclusion criteria

* History of conjunctivitis or any ocular infection within the past 3 weeks. * Any active inflammation of the cornea or the anterior chamber (uveitis)

Design outcomes

Primary

Measure	Time frame	Description
Aqueous humor proteome	Change from baseline at 6 months	The aqueous humor proteome will be assessed with liquid chromotography/mass spectometry (quantitative LC-MS/MS).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026